What is HC Wainwright's Estimate for NeuroPace Q3 Earnings?

Key Points

• HC Wainwright has reduced its Q3 2025 earnings per share estimate for NeuroPace to ($0.22), down from a prior estimate of ($0.21), while maintaining a "Buy" rating and a target price of $18.00.
• NeuroPace reported a Q2 loss of ($0.26) EPS, missing the consensus estimate of ($0.24), despite revenue of $23.52 million surpassing expectations.
• Analysts have varied ratings on NeuroPace, with five giving it a buy rating and an average target price of $16.60, indicating mixed confidence in the stock's future performance.

NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Investment analysts at HC Wainwright cut their Q3 2025 earnings per share (EPS) estimates for shares of NeuroPace in a research note issued on Thursday, August 14th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.22) per share for the quarter, down from their previous estimate of ($0.21). HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for NeuroPace's current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for NeuroPace's Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.90) EPS and FY2026 earnings at ($0.96) EPS.

Several other equities analysts have also issued reports on NPCE. JPMorgan Chase & Co. boosted their price objective on NeuroPace from $14.00 to $16.00 and gave the company an "overweight" rating in a research report on Wednesday, May 14th. Wells Fargo & Company dropped their price objective on NeuroPace from $17.00 to $15.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 13th. Zacks Research lowered NeuroPace from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 13th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $17.00 target price on shares of NeuroPace in a report on Wednesday, May 14th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $16.60.

NeuroPace Trading Up 4.3%

Shares of NeuroPace stock traded up $0.37 during trading on Monday, hitting $8.99. 156,232 shares of the company were exchanged, compared to its average volume of 216,525. The company has a debt-to-equity ratio of 3.02, a current ratio of 5.47 and a quick ratio of 4.51. The firm's fifty day moving average price is $9.57 and its 200 day moving average price is $11.55. NeuroPace has a 1-year low of $5.45 and a 1-year high of $18.98. The firm has a market capitalization of $297.39 million, a P/E ratio of -10.70 and a beta of 1.89.

NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The company had revenue of $23.52 million for the quarter, compared to analyst estimates of $23.08 million. NeuroPace had a negative return on equity of 168.61% and a negative net margin of 29.29%. NeuroPace has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On NeuroPace

Several large investors have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. grew its stake in NeuroPace by 83.6% in the second quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company's stock valued at $27,000 after acquiring an additional 1,118 shares during the period. BNP Paribas Financial Markets bought a new stake in NeuroPace during the fourth quarter worth $29,000. Legal & General Group Plc raised its stake in shares of NeuroPace by 86.0% in the second quarter. Legal & General Group Plc now owns 2,679 shares of the company's stock valued at $30,000 after buying an additional 1,239 shares during the period. Quantbot Technologies LP bought a new stake in shares of NeuroPace in the second quarter valued at $35,000. Finally, GAMMA Investing LLC bought a new stake in shares of NeuroPace in the first quarter valued at $53,000. Institutional investors and hedge funds own 78.83% of the company's stock.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.